Spotlight on Gynecology/Obstetrics

Martina C. Murphy, MD
Credits: 1.0 CME
Contemporary Treatment of Endometrial Cancer: An In The Clinic Activity
Martina C. Murphy, MD
Integrity Continuing Education, Inc.

Contemporary Treatment of Endometrial Cancer: An In The Clinic Activity

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: June 30, 2022
Expires: June 30, 2023
60 minutes to complete

Provided By

Integrity Continuing Education, Inc.

Statement of Commercial Support

This educational activity is supported by educational grants from Eisai Inc., GlaxoSmithKline, and Merck Sharp & Dohme Corp.

Target Audience

This educational activity has been designed to meet the needs of medical and gynecologic oncologists, physician assistants, and nurse practitioners who treat and manage patients with gynecologic malignancies, with a focus on the community-based clinician.

Activity Description

The treatment options for advanced or recurrent endometrial cancer (EC) have changed dramatically in the last five years. Molecular testing to identify patients that could benefit from targeted treatments is now recommended for all patients. Choosing the optimal treatment can be complex as treatment planning must consider molecular signatures, safety and efficacy data, patient and tumor characteristics, and guideline recommendations.

In this edition of In the Clinic, Drs. Murphy and Westin will unpack the latest clinical trial data and review best practices for approaching treatment for these patients.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Elucidate the necessity for genetic and molecular testing to aid in selecting appropriate monotherapeutic or combination treatment options to improve survival outcomes in patients with advanced or recurrent EC
  • Devise a strategy to incorporate recently approved or emerging treatment options for patients with advanced or recurrent EC based on clinical trial findings
  • Identify and monitor for, as well as manage and mitigate against, adverse reactions that can be caused by treatments that were recently approved for advanced or recurrent EC

Faculty Co-Chairs

Martina C. Murphy, MD
Associate Professor of Medicine
Director, UFCOM Introduction to Clinical Medicine 1A & 1B
Program Director
Hematology/Oncology Fellowship
University of Florida
Gainesville, Florida

Martina C. Murphy, MD, does not have any real or apparent conflicts to disclose.


Shannon N. Westin, MD, MPH
Associate Professor of Medicine
Director, Early Drug Development
Department of Gynecologic Oncology and Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Grants/Contracts: AstraZeneca, Bayer, Clovis Oncology, Cotinga Pharmaceuticals, GlaxoSmithKline, Mereo, Novartis, OncXerna, Roche/Genentech, Zentalis
Consulting Fees: Agenus, AstraZeneca, Caris, Clovis Oncology, Eisai, EQRx, GlaxoSmithKline, ImmunoGen, Karyopharm, Lilly, Merck, Mereo, Mersana, Roche/Genentech, Vincerx, Zentalis

Case Development Faculty

Michaela Onstad-Grinsfelder, MD, MPH
Assistant Professor
Department of Gynecologic Oncology and Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Michaela Onstad-Grinsfelder, MD, MPH, does not have any real or apparent conflicts to disclose.

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The Integrity Continuing Education, Inc. planners/managers do not have any conflicts of interest to disclose.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this Enduring material for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of June 30, 2022 through June 30, 2023, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: June 30, 2022
Expires: June 30, 2023
60 minutes to complete

Provided By

Integrity Continuing Education, Inc.

Statement of Commercial Support

This educational activity is supported by educational grants from Eisai Inc., GlaxoSmithKline, and Merck Sharp & Dohme Corp.

Target Audience

This educational activity has been designed to meet the needs of medical and gynecologic oncologists, physician assistants, and nurse practitioners who treat and manage patients with gynecologic malignancies, with a focus on the community-based clinician.

Activity Description

The treatment options for advanced or recurrent endometrial cancer (EC) have changed dramatically in the last five years. Molecular testing to identify patients that could benefit from targeted treatments is now recommended for all patients. Choosing the optimal treatment can be complex as treatment planning must consider molecular signatures, safety and efficacy data, patient and tumor characteristics, and guideline recommendations.

In this edition of In the Clinic, Drs. Murphy and Westin will unpack the latest clinical trial data and review best practices for approaching treatment for these patients.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Elucidate the necessity for genetic and molecular testing to aid in selecting appropriate monotherapeutic or combination treatment options to improve survival outcomes in patients with advanced or recurrent EC
  • Devise a strategy to incorporate recently approved or emerging treatment options for patients with advanced or recurrent EC based on clinical trial findings
  • Identify and monitor for, as well as manage and mitigate against, adverse reactions that can be caused by treatments that were recently approved for advanced or recurrent EC

Faculty Co-Chairs

Martina C. Murphy, MD
Associate Professor of Medicine
Director, UFCOM Introduction to Clinical Medicine 1A & 1B
Program Director
Hematology/Oncology Fellowship
University of Florida
Gainesville, Florida

Martina C. Murphy, MD, does not have any real or apparent conflicts to disclose.


Shannon N. Westin, MD, MPH
Associate Professor of Medicine
Director, Early Drug Development
Department of Gynecologic Oncology and Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Grants/Contracts: AstraZeneca, Bayer, Clovis Oncology, Cotinga Pharmaceuticals, GlaxoSmithKline, Mereo, Novartis, OncXerna, Roche/Genentech, Zentalis
Consulting Fees: Agenus, AstraZeneca, Caris, Clovis Oncology, Eisai, EQRx, GlaxoSmithKline, ImmunoGen, Karyopharm, Lilly, Merck, Mereo, Mersana, Roche/Genentech, Vincerx, Zentalis

Case Development Faculty

Michaela Onstad-Grinsfelder, MD, MPH
Assistant Professor
Department of Gynecologic Oncology and Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Michaela Onstad-Grinsfelder, MD, MPH, does not have any real or apparent conflicts to disclose.

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The Integrity Continuing Education, Inc. planners/managers do not have any conflicts of interest to disclose.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this Enduring material for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of June 30, 2022 through June 30, 2023, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

Gynecology/Obstetrics Presentations

Martina C. Murphy, MD
1.0 CME
Integrity Continuing Education, Inc.
Contemporary Treatment of Endometrial Cancer: An In The Clinic Activity

Contemporary Treatment of Endometrial Cancer: An In The Clinic Activity

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: June 30, 2022
Expires: June 30, 2023
60 minutes to complete

Provided By

Integrity Continuing Education, Inc.

Statement of Commercial Support

This educational activity is supported by educational grants from Eisai Inc., GlaxoSmithKline, and Merck Sharp & Dohme Corp.

Target Audience

This educational activity has been designed to meet the needs of medical and gynecologic oncologists, physician assistants, and nurse practitioners who treat and manage patients with gynecologic malignancies, with a focus on the community-based clinician.

Activity Description

The treatment options for advanced or recurrent endometrial cancer (EC) have changed dramatically in the last five years. Molecular testing to identify patients that could benefit from targeted treatments is now recommended for all patients. Choosing the optimal treatment can be complex as treatment planning must consider molecular signatures, safety and efficacy data, patient and tumor characteristics, and guideline recommendations.

In this edition of In the Clinic, Drs. Murphy and Westin will unpack the latest clinical trial data and review best practices for approaching treatment for these patients.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Elucidate the necessity for genetic and molecular testing to aid in selecting appropriate monotherapeutic or combination treatment options to improve survival outcomes in patients with advanced or recurrent EC
  • Devise a strategy to incorporate recently approved or emerging treatment options for patients with advanced or recurrent EC based on clinical trial findings
  • Identify and monitor for, as well as manage and mitigate against, adverse reactions that can be caused by treatments that were recently approved for advanced or recurrent EC

Faculty Co-Chairs

Martina C. Murphy, MD
Associate Professor of Medicine
Director, UFCOM Introduction to Clinical Medicine 1A & 1B
Program Director
Hematology/Oncology Fellowship
University of Florida
Gainesville, Florida

Martina C. Murphy, MD, does not have any real or apparent conflicts to disclose.


Shannon N. Westin, MD, MPH
Associate Professor of Medicine
Director, Early Drug Development
Department of Gynecologic Oncology and Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Grants/Contracts: AstraZeneca, Bayer, Clovis Oncology, Cotinga Pharmaceuticals, GlaxoSmithKline, Mereo, Novartis, OncXerna, Roche/Genentech, Zentalis
Consulting Fees: Agenus, AstraZeneca, Caris, Clovis Oncology, Eisai, EQRx, GlaxoSmithKline, ImmunoGen, Karyopharm, Lilly, Merck, Mereo, Mersana, Roche/Genentech, Vincerx, Zentalis

Case Development Faculty

Michaela Onstad-Grinsfelder, MD, MPH
Assistant Professor
Department of Gynecologic Oncology and Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Michaela Onstad-Grinsfelder, MD, MPH, does not have any real or apparent conflicts to disclose.

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The Integrity Continuing Education, Inc. planners/managers do not have any conflicts of interest to disclose.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this Enduring material for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of June 30, 2022 through June 30, 2023, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit
Released: June 30, 2022
Expires: June 30, 2023
60 minutes to complete

Provided By

Integrity Continuing Education, Inc.

Statement of Commercial Support

This educational activity is supported by educational grants from Eisai Inc., GlaxoSmithKline, and Merck Sharp & Dohme Corp.

Target Audience

This educational activity has been designed to meet the needs of medical and gynecologic oncologists, physician assistants, and nurse practitioners who treat and manage patients with gynecologic malignancies, with a focus on the community-based clinician.

Activity Description

The treatment options for advanced or recurrent endometrial cancer (EC) have changed dramatically in the last five years. Molecular testing to identify patients that could benefit from targeted treatments is now recommended for all patients. Choosing the optimal treatment can be complex as treatment planning must consider molecular signatures, safety and efficacy data, patient and tumor characteristics, and guideline recommendations.

In this edition of In the Clinic, Drs. Murphy and Westin will unpack the latest clinical trial data and review best practices for approaching treatment for these patients.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Elucidate the necessity for genetic and molecular testing to aid in selecting appropriate monotherapeutic or combination treatment options to improve survival outcomes in patients with advanced or recurrent EC
  • Devise a strategy to incorporate recently approved or emerging treatment options for patients with advanced or recurrent EC based on clinical trial findings
  • Identify and monitor for, as well as manage and mitigate against, adverse reactions that can be caused by treatments that were recently approved for advanced or recurrent EC

Faculty Co-Chairs

Martina C. Murphy, MD
Associate Professor of Medicine
Director, UFCOM Introduction to Clinical Medicine 1A & 1B
Program Director
Hematology/Oncology Fellowship
University of Florida
Gainesville, Florida

Martina C. Murphy, MD, does not have any real or apparent conflicts to disclose.


Shannon N. Westin, MD, MPH
Associate Professor of Medicine
Director, Early Drug Development
Department of Gynecologic Oncology and Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Grants/Contracts: AstraZeneca, Bayer, Clovis Oncology, Cotinga Pharmaceuticals, GlaxoSmithKline, Mereo, Novartis, OncXerna, Roche/Genentech, Zentalis
Consulting Fees: Agenus, AstraZeneca, Caris, Clovis Oncology, Eisai, EQRx, GlaxoSmithKline, ImmunoGen, Karyopharm, Lilly, Merck, Mereo, Mersana, Roche/Genentech, Vincerx, Zentalis

Case Development Faculty

Michaela Onstad-Grinsfelder, MD, MPH
Assistant Professor
Department of Gynecologic Oncology and Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Michaela Onstad-Grinsfelder, MD, MPH, does not have any real or apparent conflicts to disclose.

Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The Integrity Continuing Education, Inc. planners/managers do not have any conflicts of interest to disclose.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this Enduring material for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of June 30, 2022 through June 30, 2023, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

Risa Kagan, MD, FACOG, CCD, NCMP
0.25 CME / MOC
Vindico Medical Education
Vasomotor Symptoms in Menopause: Prevalence, Burden, and Impact on Quality of Life

Vasomotor Symptoms in Menopause: Prevalence, Burden, and Impact on Quality of Life

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 ABIM MOC Point(s)
Released: November 30, 2021
Expires: November 29, 2022
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is gynecologists, obstetricians, family medicine physicians, internists, physician assistants, nurse practitioners, and other health care professionals involved in the management of patients with menopause-related vasomotor symptoms.

Learning Objective

Upon successful completion of this activity, participants should be better able to assess the prevalence, burden, and impact of vasomotor symptoms during menopause on patient quality of life.

Faculty

Risa Kagan, MD, FACOG, CCD, NCMP
Clinical Professor
Department of Obstetrics, Gynecology and Reproductive Sciences
University of California San Francisco
Sutter East Bay Medical Group
Affiliated with Sutter East Bay Medical Foundation
Berkeley, CA

Disclosure:
Consultant: Astellas, Pharmavite, TherapeuticsMD
Speaker Contracted by Ineligible Company: TherapeuticsMD

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objective, answer the polling and pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Astellas.

Disclaimer

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 ABIM MOC Point(s)
Released: November 30, 2021
Expires: November 29, 2022
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is gynecologists, obstetricians, family medicine physicians, internists, physician assistants, nurse practitioners, and other health care professionals involved in the management of patients with menopause-related vasomotor symptoms.

Learning Objective

Upon successful completion of this activity, participants should be better able to assess the prevalence, burden, and impact of vasomotor symptoms during menopause on patient quality of life.

Faculty

Risa Kagan, MD, FACOG, CCD, NCMP
Clinical Professor
Department of Obstetrics, Gynecology and Reproductive Sciences
University of California San Francisco
Sutter East Bay Medical Group
Affiliated with Sutter East Bay Medical Foundation
Berkeley, CA

Disclosure:
Consultant: Astellas, Pharmavite, TherapeuticsMD
Speaker Contracted by Ineligible Company: TherapeuticsMD

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objective, answer the polling and pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Astellas.

Disclaimer

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Nanette Santoro, MD
0.25 CME / MOC
Vindico Medical Education
Treating Vasomotor Symptoms in Menopause: Current and Emerging Therapies

Treating Vasomotor Symptoms in Menopause: Current and Emerging Therapies

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 ABIM MOC Point(s)
Released: November 30, 2021
Expires: November 29, 2022
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is gynecologists, obstetricians, family medicine physicians, internists, physician assistants, nurse practitioners, and other health care professionals involved in the management of patients with menopause-related vasomotor symptoms.

Learning Objective

Upon successful completion of this activity, participants should be better able to review the mechanisms of action and clinical evidence regarding the safety and efficacy of emerging treatment options for vasomotor symptoms in menopause, including the benefits and limitations of current therapies.

Faculty

Nanette Santoro, MD
Professor and E. Stewart Taylor Chair of Obstetrics and Gynecology
University of Colorado School of Medicine
Aurora, CO

Disclosure:
Advisor: Astellas

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objective, answer the polling and pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Astellas.

Disclaimer

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 ABIM MOC Point(s)
Released: November 30, 2021
Expires: November 29, 2022
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is gynecologists, obstetricians, family medicine physicians, internists, physician assistants, nurse practitioners, and other health care professionals involved in the management of patients with menopause-related vasomotor symptoms.

Learning Objective

Upon successful completion of this activity, participants should be better able to review the mechanisms of action and clinical evidence regarding the safety and efficacy of emerging treatment options for vasomotor symptoms in menopause, including the benefits and limitations of current therapies.

Faculty

Nanette Santoro, MD
Professor and E. Stewart Taylor Chair of Obstetrics and Gynecology
University of Colorado School of Medicine
Aurora, CO

Disclosure:
Advisor: Astellas

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objective, answer the polling and pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Astellas.

Disclaimer

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com